Ralph Minter, Ph.D. presented “Resilience-Associated CD33 Antibody ATLX-1088, A Potent Stimulator of Microglial Phagocytosis” at AD/PD 2024, the International Conference on Alzheimer’s and Parkinson’s Diseases held 6th March 2024. Learn More.
Alchemab publication and NeurIPS Machine Learning in Structural Biology workshop. Click to read more.
View Publication
View Publication
Michelle Sidor and Iosif Pediaditakis presented the following posters: ‘Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology’ and ‘Netrin-1 and neurodegenerative diseases: Unraveling Therapeutic Avenues’. Learn More
Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023. Our innovative, target agnostic discovery platform, which combines data analysis of hundreds of millions of individual antibodies with […]
15 June 2021 – Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity. Read full article
14 June 2021 – We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London. Read full article
15 December 2020 – Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients. Clonal expansion of the B cell population is also observed and may be the result of memory bystander effects. Read […]
5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices. Read full article